Subscribe Alumni Newsroom Offices Contact Us About Us Careers

Sectors

Energy & Infrastructure

Innovation in Energy & Infrastructure

Aerial view of a city at night with illuminated grid-like streets and buildings under a cloudy sky, lines and dots digitally added to emphasize the city grid layout, reflecting the structured precision found in top law offices.

Airport & Aviation

Aviation & Aircraft Transactions

Food & Beverage

Regulatory Compliance, Food Safety

Infringement Litigation, Leasing

Health Care & Life Sciences

Advances in Health Care & Life Sciences

Banking & Finance, Cannabis Litigation

Hospitality & Leisure

Hotels & Resorts, Golf Clubs

Sports & Entertainment

Sports Facility Development, Media Deals

Innovative Technology

Leveraging AI, Cloud Computing, Genomics

Generational Wealth, Wealth Management

Offshore Oil & Gas, Admiralty Law

Manufacturing

End-to-End Business Solutions

Fashion, Apparel & Beauty

Trademark, Manufacturing, Supply Chain

Racial Justice & Equity

Public Affairs, Small Business Services

All Practice Areas

Corporate

Corporate Overview

Capital Markets & Public Company Advisory Equity, Debt, Governance, Transactions

Employee Benefits & Executive Compensation Health Plans, 401 (k), and Pension Plans

Environmental Permitting, Environmental Litigation

Environmental, Social, and Governance (ESG) Impact Investing, Energy Transition

Estate Planning Family Offices, Wealth Management, Trust

Finance Financial Institutions, Public Private Partnerships

Fund Formation & Investment Management GPs, LPs, Middle Market Investment

Government Solutions Lobbying, Policy, State Attorneys General

Health Care Health Care Regulatory and Transactions

Insurance Reinsurance, Insurance Transactions

Private Equity Middle Market PE, Investment Lifecycle

Real Estate Real Estate Law, Commercial Development

Securities, Commodities & Exchange Regulation Securities Law, Commodities

Taxation State and Local Tax, Opportunity Zones

Transactions Mergers and Acquisitions

Venture & Growth Capital Angel Funds, Venture Funds

Intellectual Property

Intellectual Property Overview

Business Method & Software Patents Software Patent Counseling and Litigation

Chemical, Biotechnology & Pharmaceutical Full Cycle Patent Strategy and Services

Cybersecurity Cyber Risk Mitigation and Response

Electronics Full Cycle Patent Strategy and Services

Green Energy Technologies Cleantech, Smart Grid, Biofuels

IP Asset Management IP Portfolio Strategy and Management

IP Due Diligence IP Audit, Investment, and Monetization

IP Litigation IP Asset Enforcement and Defense

ITC Section 337 Proceedings IP Import Infringement Investigations

Mechanical & Electromechanical Technologies Full Cycle Patent Strategy and Services

PTAB Trials Post-Grant Proceedings

Technology Transactions, Cybersecurity, and Privacy IT Contracting and Data Governance

Trademark, Copyright & Advertising Counseling Trademark Protection, Copyright Defense

Litigation

Litigation Overview

Antitrust & Competition Antitrust Litigation, Antitrust Regulation

Appellate Appellate Attorneys

Bankruptcy & Business Reorganizations Asset Acquisition, Restructuring

Commercial Litigation Bet the Company Litigation, eDiscovery

Construction Construction Litigation, Arbitrations

Consumer Law, Finance & Class Action Group Consumer Class Action Defense

Distribution & Franchise Antitrust and Competition, Trademarks

Energy Litigation Oil & Gas Litigation, Dispute Resolution

Government Enforcement Defense & Investigations False Claims Act, International Trade

Health Care Litigation Dispute Resolution, Civil Lawsuits

Hospitality Litigation TCPA Compliance, Franchise Disputes

Insurance & Reinsurance Litigation Casualty Insurance, Insurance Fraud

International Arbitration Cross-Border Dispute Resolution

Labor & Employment Union/Employer Matters, Harassment Claims

Privacy, Security & Information Management Privacy Litigation, Privacy Compliance

Product Liability Life Sciences Product Liability

Securities Enforcement & Litigation SEC Enforcement, Auditor Defense

Tax Controversy Tax Dispute, Tax Audit, Tax Litigation

Trade Secret Noncompete Litigation Unfair Competition, Noncompete Agreement

Trial Team Federal & State Courts, Jury Trials

English

Popular Searches

IP Litigation
Trump Administration Resources
Patent
Energy & Infrastructure
Artificial Intelligence

Brinckerhoff Quoted on Mayo v. Prometheus

March 20, 2012 Reuters

Share on LinkedIn

Share on Twitter

Discussing the Supreme Court’s decision in Mayo v. Prometheus to reject two patents on a method for monitoring a patient’s blood to determine appropriate drug dosage as well as the decision’s potential to affect the profitability of personalized medicine, Partner Courtenay Brinckerhoff said the rejection is a disruption of the status quo that may result in less funding for research. First published in an article that appeared in Reuters, Ms. Brinckerhoff’s comments later appeared in additional publications including the Chicago Tribune, Yahoo! News, BioPortfolio and The Huffington Post.

People

Courtenay C. Brinckerhoff

Sectors

Practice Areas

Chemical, Biotechnology & Pharmaceutical

People

A woman with short light brown hair and glasses, wearing a gray turtleneck, dark blazer, and pearl necklace, smiles in a blurred corporate law office hallway background.

Courtenay C. Brinckerhoff

[email protected]

Washington, D.C. 202.295.4094

Related News

May 1, 2026 In the News

David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute

Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.

April 27, 2026 In the News

Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards

Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.

April 27, 2026 In the News

David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures

Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.

We look beyond the law to focus on the constantly evolving demands facing our clients.

Cookie Preferences

© 2026 Foley & Lardner LLP

Attorney Advertisement

Images of people may not be Foley personnel.

Connect on LinkedIn

Connect on Instagram

Connect on Facebook

Connect on Twitter

Connect on Youtube